Domestic anti-obesity drug era opens, yet industry already targets 'Post-GLP-1'
Hanmi Pharmaceutical's "Eppe" (ingredient: efpeglenatide) has been approved as South Korea's 45th novel drug and the first domestic GLP-1 class anti-obesity treatment, ushering in the era of homegrown obesity therapeutics. However, the domestic and international pharmaceutical and biotech industries have already turned their sights to the next GLP-1 market,..